Citigroup Maintains Buy on Cytokinetics, Lowers Price Target to $80

Benzinga · 4d ago
Citigroup analyst David Lebowitz maintains Cytokinetics (NASDAQ:CYTK) with a Buy and lowers the price target from $86 to $80.